Mustang Bio launches clinical study combining CAR T cells and oncolytic virus to treat glioblastoma

The cell and gene therapy company Mustang Bio (Nasdaq:MBIO) will initiate a Phase 1 clinical trial combining CAR T cells and oncolytic virus as a potential therapy for recurrent glioblastoma.

The prognosis for glioblastoma is generally poor with approximately 40% survival in the first year following diagnosis, according to the American Association of Neurological Surgeons.

The Worcester, Massachusetts–based company made the announcement after reviewing interim data from two ongoing investigator-sponsored Phase 1 clinical studies testing MB-108 (C134 oncolytic virus) and MB‐101 (City of Hope’s IL13Rα2‐targeted CAR T cell therapy).

Mustang Bio recently shared data supporting the safety of administering MB-108 and MB-101 sequentially in a regimen designated as MB-109 at the American Association for Cancer Research (AACR) Annual Meeting 2022.

“The data presented at the AACR Annual Meeting support the initiation of a Phase 1 clinical trial to evaluate …

Read more
  • 0